Holen Sie sich die Stockscreener-App
7.21
0.56%
0.04
Schlusskurs vom Vortag:
$7.17
Offen:
$7.16
24-Stunden-Volumen:
318.63K
Relative Volume:
0.49
Marktkapitalisierung:
$204.87M
Einnahmen:
$157.75M
Nettoeinkommen (Verlust:
$-29.73M
KGV:
-6.2155
EPS:
-1.16
Netto-Cashflow:
$-21.00M
1W Leistung:
-4.76%
1M Leistung:
-4.76%
6M Leistung:
-62.47%
1J Leistung:
-56.06%
1-Tages-Spanne:
$7.05
$7.45
1-Wochen-Bereich:
$7.05
$7.94
52-Wochen-Spanne:
$5.85
$24.17
Arcturus Therapeutics Holdings Inc Stock (ARCT) Company Profile
Firmenname
Arcturus Therapeutics Holdings Inc
Sektor
Branche
Telefon
(858) 900-2660
Adresse
10285 SCIENCE CENTER DRIVE, SAN DIEGO, CA
Compare ARCT vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ARCT
Arcturus Therapeutics Holdings Inc
|
7.21 | 203.73M | 157.75M | -29.73M | -21.00M | -1.16 |
|
VRTX
Vertex Pharmaceuticals Inc
|
491.47 | 117.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
803.17 | 82.85B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
821.96 | 51.58B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.40 | 40.75B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.07 | 38.33B | 4.98B | 69.60M | 525.67M | 0.5198 |
Arcturus Therapeutics Holdings Inc Stock (ARCT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-23 | Eingeleitet | Roth Capital | Buy |
| 2025-10-24 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2025-10-23 | Herabstufung | Citigroup | Buy → Neutral |
| 2025-10-22 | Herabstufung | Guggenheim | Buy → Neutral |
| 2025-09-04 | Fortgesetzt | H.C. Wainwright | Buy |
| 2025-05-28 | Eingeleitet | Scotiabank | Sector Outperform |
| 2025-01-28 | Eingeleitet | BTIG Research | Buy |
| 2024-08-12 | Eingeleitet | Leerink Partners | Outperform |
| 2023-12-13 | Eingeleitet | Canaccord Genuity | Buy |
| 2023-07-24 | Eingeleitet | William Blair | Outperform |
| 2023-05-11 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2022-11-14 | Fortgesetzt | Wells Fargo | Overweight |
| 2022-11-10 | Herabstufung | Robert W. Baird | Neutral → Underperform |
| 2022-11-03 | Hochstufung | Citigroup | Neutral → Buy |
| 2022-11-02 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2022-08-10 | Herabstufung | Raymond James | Mkt Perform → Underperform |
| 2022-07-19 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2022-05-11 | Hochstufung | Robert W. Baird | Underperform → Neutral |
| 2022-04-21 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-01-31 | Hochstufung | Raymond James | Underperform → Mkt Perform |
| 2021-08-12 | Herabstufung | Raymond James | Mkt Perform → Underperform |
| 2021-08-11 | Herabstufung | Goldman | Neutral → Sell |
| 2021-08-10 | Herabstufung | Robert W. Baird | Neutral → Underperform |
| 2021-07-02 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-06-25 | Fortgesetzt | Goldman | Neutral |
| 2021-06-21 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2021-06-04 | Fortgesetzt | Robert W. Baird | Neutral |
| 2021-02-17 | Herabstufung | B. Riley Securities | Neutral → Sell |
| 2021-01-19 | Herabstufung | B. Riley Securities | Buy → Neutral |
| 2021-01-15 | Herabstufung | B. Riley Securities | Buy → Neutral |
| 2021-01-07 | Eingeleitet | Wells Fargo | Overweight |
| 2020-12-29 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2020-12-29 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2020-12-29 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2020-12-29 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2020-12-23 | Herabstufung | ROTH Capital | Buy → Sell |
| 2020-12-08 | Bestätigt | B. Riley Securities | Buy |
| 2020-12-07 | Bestätigt | B. Riley Securities | Buy |
| 2020-10-26 | Eingeleitet | Barclays | Overweight |
| 2020-10-06 | Eingeleitet | Citigroup | Buy |
| 2020-08-26 | Eingeleitet | Piper Sandler | Overweight |
| 2020-07-30 | Fortgesetzt | ROTH Capital | Buy |
| 2020-07-16 | Eingeleitet | Raymond James | Outperform |
| 2020-07-13 | Eingeleitet | B. Riley FBR | Buy |
| 2020-06-09 | Herabstufung | WBB Securities | Buy → Hold |
| 2020-02-11 | Eingeleitet | Robert W. Baird | Outperform |
| 2020-02-07 | Eingeleitet | Guggenheim | Buy |
| 2020-02-06 | Eingeleitet | Guggenheim | Buy |
| 2019-04-05 | Eingeleitet | H.C. Wainwright | Buy |
| 2018-09-20 | Hochstufung | WBB Securities | Buy → Strong Buy |
| 2018-01-22 | Eingeleitet | Chardan Capital Markets | Buy |
Alle ansehen
Arcturus Therapeutics Holdings Inc Aktie (ARCT) Neueste Nachrichten
Arcturus cut to Neutral at Citi on data for mRNA candidate - MSN
Arcturus Therapeutics: Two Catalysts, One Runway, And A Stock Priced For Failure - Seeking Alpha
Is Arcturus Therapeutics Holdings Inc. stock a buy before product launches - mfd.ru
Arcturus at Guggenheim Biotech Summit: Strategic Advances in mRNA Therapies - Investing.com Canada
Arcturus Therapeutics Spotlights Inhaled mRNA CF Phase 2b Plan, FDA Talks for OTC Program at Summit - MarketBeat
Citi Lowers Price Target on Arcturus Therapeutics Holdings Inc. (ARCT) to $7, Maintains Neutral Rating - Finviz
Citi lowers price target on Arcturus Therapeutics Holdings Inc. (ARCT) to $7, maintains neutral rating - MSN
Trading the Move, Not the Narrative: (ARCT) Edition - Stock Traders Daily
Aug Drivers: Is Arcturus Therapeutics Holdings Inc vulnerable to short sellers2025 Price Momentum & Weekly High Conviction Ideas - baoquankhu1.vn
Arcturus Therapeutics (NASDAQ:ARCT) Shares Cross Below 200-Day Moving AverageHere's Why - MarketBeat
Arcturus Therapeutics (NASDAQ:ARCT) Shares Pass Below Two Hundred Day Moving AverageTime to Sell? - MarketBeat
Roth Capital Say Market Pricing Implies Zero Success for Arcturus Therapeutics Holdings Inc. (ARCT) Pipeline Assets - MSN
Arcturus Therapeutics warns of severe risks from OTC deficiency - Traders Union
Arcturus Therapeutics Holdings (ARCT) Stock Analysis: A Biotech with 355% Potential Upside - DirectorsTalk Interviews
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
(ARCT) Volatility Zones as Tactical Triggers - Stock Traders Daily
Should value investors consider Arcturus Therapeutics Holdings Inc.Breakout Watch & Advanced Technical Signal Analysis - mfd.ru
Arcturus Therapeutics (NASDAQ:ARCT) Stock Rating Upgraded by Roth Mkm - MarketBeat
Roth/MKM initiates coverage on Arcturus Therapeutics stock with Buy rating - Investing.com India
Stifel Initiates Arcturus Therapeutics(ARCT.US) With Buy Rating, Announces Target Price $20 - 富途资讯
Roth/MKM initiates coverage on Arcturus Therapeutics stock with Buy rating By Investing.com - Investing.com South Africa
Arcturus Therapeutics Holdings (ARCT) Stock Analysis: Is a 384.87% Upside Potential Within Reach? - DirectorsTalk Interviews
Arcturus Therapeutics Holdings (ARCT) Price Target Decreased by 28.26% to 32.77 - MSN
Arcturus wins FDA fast track status for influenza vaccine - MSN
Price-Driven Insight from (ARCT) for Rule-Based Strategy - Stock Traders Daily
Market Review: How liquid is Arcturus Therapeutics Holdings Inc stockJuly 2025 Summary & Growth Focused Entry Point Reports - baoquankhu1.vn
Analysis Recap: Should value investors consider Arcturus Therapeutics Holdings Inc2025 Valuation Update & Fast Moving Market Watchlists - baoquankhu1.vn
Aug EndMonth: Should value investors consider Arcturus Therapeutics Holdings Inc2025 Market Overview & Risk Controlled Swing Alerts - baoquankhu1.vn
FEDERATED HERMES, INC. Reduces Stake in Arcturus Therapeutics Ho - GuruFocus
Does Arcturus Therapeutics (ARCT) JPM Conference Spotlight Clarify Its Long-Term Platform Credibility? - simplywall.st
Aug EndMonth: Should I hold or sell Arcturus Therapeutics Holdings Inc stock in 2025July 2025 Update & AI Powered Buy and Sell Recommendations - Bộ Nội Vụ
Arcturus Therapeutics Holdings (ARCT) Valuation Check As J.P. Morgan Healthcare Conference Presentation Nears - Yahoo Finance
Arcturus Therapeutics Maps Near-Term Milestones for CF mRNA Therapy, ARCT-810 at J.P. Morgan Conference - MarketBeat
ARCT: Advancing mRNA therapies for CF and OTC with strong data, regulatory focus, and solid funding - TradingView
Is Arcturus Therapeutics (ARCT) Using Its $500 Million Shelf to Redefine Capital Strategy? - Yahoo Finance
Ag Plus, Inc. - Ag Plus, Inc.
1 Under-$10 Stock Set to Surge as Much as 963% in 2026 - Yahoo Finance
Will Arcturus Therapeutics Holdings Inc. stock maintain momentum in 2025Portfolio Profit Report & AI Driven Stock Movement Reports - ulpravda.ru
Arcturus Gets FDA's Fast Track Tag for Influenza Vaccine Candidate - MSN
Arcturus Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference - BioSpace
Can Arcturus Therapeutics Holdings Inc. stock rebound after recent weaknessPortfolio Profit Report & Precise Entry and Exit Recommendations - Улправда
Is Arcturus Therapeutics Holdings Inc. stock positioned well for digital economyJuly 2025 Selloffs & Scalable Portfolio Growth Ideas - Улправда
Earnings Beat: Can Arcturus Therapeutics Holdings Inc. stock rebound after recent weaknessWeekly Earnings Recap & Real-Time Volume Surge Alerts - Улправда
Arcturus Therapeutics Holdings (ARCT): Analyst Ratings Suggest a Staggering 415% Upside Potential - DirectorsTalk Interviews
Citigroup Lowers Price Target for ARCT, Maintains Neutral Rating | ARCT Stock News - GuruFocus
(ARCT) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
UK Regulator OKs Arcturus Therapeutics' COVID-19 Booster Jab - MarketScreener
MHRA approves Kostaive mRNA COVID-19 vaccine - The Pharma Letter
What analysts say about Arcturus Therapeutics Holdings Inc stockStraddle and Strangle Trades & Investment Case Studies - earlytimes.in
Arcturus Therapeutics (NASDAQ:ARCT) Share Price Passes Below Two Hundred Day Moving AverageTime to Sell? - MarketBeat
Finanzdaten der Arcturus Therapeutics Holdings Inc-Aktie (ARCT)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.12%
0.87%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):